Geode Capital Management
DAWN

Geode Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Geode Capital Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.9M Buy
1,954,735
+76,897
+4% +$1.08M ﹤0.01% 1586
2025
Q4 		$17.5M Buy
1,877,838
+116,574
+7% +$974K ﹤0.01% 2084
2025
Q3 		$12.4M Buy
1,761,264
+48,835
+3% +$336K ﹤0.01% 2287
2025
Q2 		$11.1M Buy
1,712,429
+171,964
+11% +$1.18M ﹤0.01% 2293
2025
Q1 		$12.2M Buy
1,540,465
+77,483
+5% +$835K ﹤0.01% 2166
2024
Q4 		$18.5M Buy
1,462,982
+30,285
+2% +$421K ﹤0.01% 2007
2024
Q3 		$20M Buy
1,432,697
+136,458
+11% +$1.95M ﹤0.01% 1976
2024
Q2 		$17.9M Sell
1,296,239
-80,722
-6% -$1.18M ﹤0.01% 1992
2024
Q1 		$22.8M Buy
1,376,961
+28,142
+2% +$421K ﹤0.01% 1853
2023
Q4 		$19.7M Buy
1,348,819
+55,705
+4% +$675K ﹤0.01% 1932
2023
Q3 		$15.9M Buy
1,293,114
+367,898
+40% +$4.8M ﹤0.01% 1967
2023
Q2 		$11M Buy
925,216
+336,740
+57% +$4.4M ﹤0.01% 2231
2023
Q1 		$7.87M Buy
588,476
+7,992
+1% +$156K ﹤0.01% 2399
2022
Q4 		$12.5M Buy
580,484
+25,854
+5% +$530K ﹤0.01% 2102
2022
Q3 		$11.1M Buy
554,630
+112,271
+25% +$2.39M ﹤0.01% 2169
2022
Q2 		$7.92M Buy
442,359
+119,664
+37% +$1.24M ﹤0.01% 2421
2022
Q1 		$3.2M Buy
322,695
+113,352
+54% +$1.5M ﹤0.01% 3026
2021
Q4 		$3.53M Buy
209,343
+22,716
+12% +$467K ﹤0.01% 3081
2021
Q3 		$4.43M Buy
186,627
+151,692
+434% +$3.64M ﹤0.01% 2974
2021
Q2 		$795K Buy
+34,935
New +$729K ﹤0.01% 3719

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Geode Capital Management's DAWN Position: Q1 2026 in Review

Geode Capital Management increased its Day One Biopharmaceuticals (DAWN) stake by 4.1% in Q1 2026, buying an estimated $1.08M and bringing the position to 1,954,735 shares worth $41.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1586.

Geode Capital Management first reported a position in DAWN in Q2 2021 and has held it in 20 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Geode Capital Management held 1,954,735 shares of Day One Biopharmaceuticals worth $41.9M as of Q1 2026.
  • Geode Capital Management bought 76,897 Day One Biopharmaceuticals shares in Q1 2026, an estimated $1.08M.
  • Day One Biopharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #1586 holding.
  • Geode Capital Management first reported a position in Day One Biopharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.